Company intelligence / Profile preview

Alethia Biotherapeutics

Montreal, Quebec, Canadaalethiabio.com ↗

Ownership: Private
Employees: ~12
Development stage: Phase 2

Overview

Alethia’s lead antibody sotevtamab (formerly AB-16B5) targets EMT by inhibiting secreted clusterin. In preclinical models, it reduced tumor invasion and improved chemotherapy response. Phase I trials showed safety/tolerability with stable disease in several patients up to one year. A completed open-label Phase II trial in NSCLC demonstrated efficacy signals; a new proof-of-concept Phase II trial in colorectal cancer with liver metastases has been initiated. Recent data from the EGIA-002 trial were presented at ASCO 2024.

Therapeutic areas: Oncology
Modalities: monoclonal antibodies (mAbs), specifically humanized IgG2 antibodies
Industry: Biotech

Drug pipeline

3 assets

sotevtamab

2 more assets in the full pipeline.

Request access →

Partnerships

Manufacturing partnership with Goodwin Biotechnologies for AB‑16B5 productionlicensing agreement with National Research Council Biotechnology Research Institute for anti-clusterin mAbs and diagnostic peptide P3378

Beyond the preview

Go deeper on Alethia Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alethia Biotherapeutics.

Explore the full profile